HPV Vaccination Programs Show Dramatic Real-World Impact, Major Review Finds
A global systematic review encompassing ecological, cross-sectional, and cohort studies has confirmed that HPV vaccination programs are producing substantial declines in multiple HPV-related diseases. Published in Expert Review of Vaccines, the analysis screened 13,549 records and ultimately included 63 studies.
Key Findings: A Significant Public Health Success
Settings with at least 70% vaccine coverage, especially when vaccination occurred before sexual debut, reported the largest reductions. School-based vaccination programs were consistently associated with high uptake rates.
The review documented impressive reductions across a range of conditions:
- HPV infection: 58–100%
- Cervical intraepithelial neoplasia grade 2 or higher (CIN2+): 30–88%
- Genital warts: 60–90%
- Invasive cervical cancer: 70–88%
- Oropharyngeal cancer: Also noted as declining
"Reductions ranged from 58–100% for HPV infection and 70–88% for invasive cervical cancer."
Global Access and Lingering Challenges
The review highlighted a stark disparity: HPV-related cancer burden remains highest in low- and middle-income countries with limited vaccination and screening access.
The authors emphasized the urgent need for expanding vaccination, improving uptake among underserved populations, and sustaining high-coverage programs to maximize benefits.
Study Limitations
The research team acknowledged several limitations, including heterogeneity in study design, outcome definitions, and follow-up periods across the included studies.
Reference: Zeleke AJ et al. Expert Rev Vaccines. 2026.